Research programme: antibody therapeutics - LEO Science and Tech Hub/Elektrofi

Drug Profile

Research programme: antibody therapeutics - LEO Science and Tech Hub/Elektrofi

Latest Information Update: 18 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LEO Science & Tech Hub
  • Developer Elektrofi; LEO Science & Tech Hub
  • Class Antibodies; Skin disorder therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Skin disorders

Most Recent Events

  • 11 Oct 2017 LEO Pharma and Elektrofi agree to co-develop antibody therapeutics using advanced formulation technology for skin disorders
  • 11 Oct 2017 Early research in Skin disorders in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top